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Abstract
Background: Proinflammatory cytokines are an integral part of the osteolytic activity of Charcot arthropathy but
are also central to normal bone healing. As there are no previous longitudinal studies investigating their role during
the recovery phase of Charcot, we set out to monitor systemic levels of proinflammatory cytokines from Charcot
presentation until a clinically and radiographically documented chronic state has been reached.
Methods: Twenty-eight consecutive Charcot patients were monitored during 2 years by repeated foot radiographs,
MRI and plasma levels of interleukin [IL]-6, IL-8, IL-1β, Tumor Necrosis Factor [TNF]-α, and IL-1 receptor antibody
(IL-1RA). Charcot patients were treated with total contact cast (TCC) on the first day of inclusion. Neuropathic
diabetic controls (n = 20) and Healthy subjects (n = 20) served as reference.
Results: Plasma IL-6, IL-8, IL-1β and TNF-α in the acute and chronic phase of Charcot were below or at the level of
diabetic controls and healthy, whereas IL-1RA/IL-1β ratio was continuously higher in Charcot patients. IL-6, TNF-α
and IL-1RA began to increase one week after offloading to reach a peak after 4 months before gradually receding.
Conclusions: A sustained increase of IL-6 and TNF-α starting shortly after offloading and paralleled by accelerated
bone healing on radiographs, suggest that offloading, by activating the inflammatory stage, has a key role to play
in the onset of coupled bone remodeling. High IL-1RA/IL-1β ratio in Charcot patients at presentation supports a
counter-balancing anti-inflammatory role for IL-1RA in the acute phase whereas a high ratio after two years,
possibly due to renewed weight-bearing on a deformed foot, signal need for continued anti-inflammatory activity
and contradicts a “cold” biological state in the chronic phase.
Keywords: Charcot arthropathy, Charcot foot, Bone healing, Fracture, Offloading, Diabetes, Neuropathy, Proinflammatory
cytokines, IL-6, IL-8, IL-1beta, TNF-alpha, IL-1 receptor antibody
Background
The Charcot foot is often characterized by local inflam-
mation, diastases, joint dislocations, and fractures. A
great number of experimental and clinical studies have
shown that most fractures heal by overlapping phases
characterized by inflammation, bone regeneration and
remodeling and that these phases normally follow a
preset schedule with a rather controlled set of events
when fracture healing is allowed to proceed undisturbed
(Fig. 1) [1, 2]. In the primary phase of fracture healing, pro-
inflammatory cytokines, such as IL-6, IL-8, IL-1β, IL-17
and TNF-α, are expressed and released within the first
hours or days after tissue injury. This initial cytokine boost
from the damaged bone and soft tissue is transitory in
nature and only lasts a few days but yet is responsible for a
number of key events such as removal of necrotic tissues
and recruitment of neutrophils and mesenchymal stem
cells [1, 3]. Stem cells are stimulated to undergo differenti-
ation into chondrocytes leading to formation of cartilagin-
ous callus that stabilizes the fracture and, when absent or
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disturbed, will have detrimental effects on mesenchymal
cell maturation and callus formation [3]. An intermediate
phase of low activity by proinflammatory cytokines follows
and is characterized by cartilaginous callus being calcified
and replaced by woven bone. A secondary or late phase of
expression and release of proinflammatory cytokines will
ensue and stimulate the transformation of stem cells into
osteoblasts and osteoclasts allowing for the coupled re-
modeling phase characterized by woven bone of the callus
being replaced with lamellar [1, 3].
We currently know little of the mechanisms triggering
the pathological changes characteristic of Charcot ar-
thropathy although trauma to the foot and the ensuing
inflammatory reaction has been proposed as an import-
ant driving force [4]. Although the acute Charcot foot
presents itself with the classical features of a local
inflammatory reaction, i.e. a red, hot and swollen foot
[5], the pathogenic role of inflammation can be multifa-
ceted as it may both play a primary role in triggering the
onset of the destructive processes leading to the anatom-
ical changes of foot, or be secondary to these changes
[6]. Inflammation, being a general response by the body
to all types of trauma, serves as an important part of the
repair and defense mechanisms, before subsiding when
the cause of inflammation has been removed or the
healing process has been allowed to proceed uninter-
rupted. A critical factor for the Charcot patient in this
context is their loss of pain as protective sensory input
and thus inability to identify the severity of trauma
which will often delay the onset of medical treatment
by weeks or months. This, in turn, will lead to con-
tinued weight-bearing on the diseased foot with
motion at fracture site causing delayed bone union
which has led clinicians globally to adopt a treatment
strategy of prolonged non-weight-bearing to create
better healing conditions [7, 8]. As proinflammatory
cytokines have been shown to play a pivotal role in
bone repair and there are no previous longitudinal
studies investigating their role in Charcot patients we
set out to monitor systemic levels from presentation
until a clinically and radiographically documented
cold/chronic state has been reached.
Fig. 1 Schematic overview of the main phases of bone fracture repair in humans
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Methods
This observational prospective study was approved 2007
by the Review Board of Västra Götalands Regionen
(EPN D-number 499–07) with additional approval 2010
(T 762–10 ad 499–07). All the subjects provided
informed consent before participating in the study. The
study complies with the STROBE-statement for observa-
tional studies [9].
Patient selection and treatment
Twenty-eight Thirty consecutive ambulatory men and
women admitted to Sahlgrenska University Hospital/
Mölndal with clinical signs of unilateral acute Char-
cot’s foot were included in the study during 2009–2013.
Two patients deceased shortly after inclusion and were ex-
cluded. 1 patient interrupted participation after 18 months
after being informed that radiographs showed finalized
bone healing, but did not object to data being processed in
the study. Diagnosis of Charcot foot was based on medical
history, clinical examination and radiological findings in-
cluding the following criteria: (1) Type 1 or 2 diabetes with
duration of ≥ 1 year (2) peripheral bilateral neuropathy as
defined below and (3) clinical signs of active Charcot ar-
thropathy with hot/reddened/swollen foot and skin
temperature in the affected foot ≥ 2 °C higher than the
contralateral foot. Off-loading treatment of the dis-
eased foot by a non-weight bearing total contact cast
(TCC) was introduced in all Charcot patients within
1 day of inclusion to the study. The TCC was
repeatedly replaced as required by changes in foot
volume due to increased or attenuated swelling. The
non-weight-bearing protocol was aided by crutches or
wheel-chair and was continued until the difference in
skin temperature between the feet was ≤ 1 °C and no
signs of redness and swelling were present for the
past 30 days. TCC was then replaced by orthosis for
partial weight-bearing. Evaluation of skin temperature
and toe pressure continued until 2 years postinclu-
sion. When full weight-bearing was allowed, the pa-
tient received prescribed accommodative shoes.
Bilateral foot radiograhs and magnetic resonance im-
aging (MRI) at inclusion and repeatedly during the
follow-up period were used to monitor fractures, dis-
locations and soft tissue-or bone marrow edema. Ex-
clusion criteria were plantar ulcerations, documented
history of trauma or surgery involving bone tissue
during the past year prior to inclusion, current im-
munosuppressive therapy (steroids, cancer treatment)
or medication known to affect bone metabolism (e.g.
bisphosphonates, denosumab). Considering the detri-
mental effects on bone healing attributed to diabetes
and peripheral neuropathy (see Discussion), a control
group of 20 ambulatory diabetes type 1 or 2 patients with
documented peripheral neuropathy was recruited at
Frölunda Specialist Hospital thus allowing us to distin-
guish changes occurring as a result of Charcot arthropathy
and its treatment. A group of healthy subjects was re-
cruited at Sahlgrenska University Hospital/Mölndal and
served as a reference to the neuropathic diabetic control
group as we were previously able to show important dif-
ferences in bone regulating cytokines between these
groups [10]. Both control groups lacked history of joint/
bone disease or bone trauma/surgery 1 year prior to inclu-
sion and received no osteoporosis medication.
Skin sensitivity, skin temperature and toe pressure
Peripheral neuropathy was assessed bilaterally by measur-
ing foot skin sensitivity in Charcot and diabetic control
patients using the Semmes-Weinstein monofilament test.
The monofilament (10 g) was pressed against 4 different
locations on the foot and the patient’s ability or inability
to feel the sensation upon buckling of the monofilament
was registered. Neuropathy was present if 3 or more sites
were insensate to the monofilament. Skin temperature
was measured bilaterally on the dorsal foot 5 cm distal of
the ankle and 2 cm proximal of the mid toe. Toe pressure
was measured bilaterally using a specially designed cuff
[11]. Measurements of skin temperature and toe pressure
were performed at inclusion, after 1 week, 2, 4, 6, 8, 12, 18
and 24 months.
Blood samples
Peripheral blood samples were collected for routine ana-
lysis (Hemoglobin, serum creatinine, CRP, SR and HbA1c).
Venous blood for biomarker analysis was sampled in pre-
chilled EDTA tubes which were immediately centrifuged
for 10 min at 4 °C and plasma was stored at −85 °C until
analysis. Blood was collected on the day of inclusion, after
1 week, 2, 4, 6, 8, 12, 18 and 24 months. Before analysis of
IL-6, IL-8, TNF-α, IL-1β and IL-1RA, samples were thawed
on ice and mounted on assay plates. The IL-1RA/IL-1β ra-
tio was calculated from IL-1RA and IL-1β data in individ-
ual patients obtained by analysis of the same batch of
patient plasma at each specific time point. Blood from
diabetes control patients and healthy subjects was sampled
on one occasion as we did not expect clinical and labora-
tory variables to undergo significant changes in these
groups during the short duration of the study. Frequent
routine laboratory monitoring in the diabetes control
group enabled us to compare laboratory data at inclusion
and 2 years later confirming that no significant laboratory/
clinical changes had occurred in this group during the
course of the study (Table 1). Biomarker data from diabetic
controls and healthy subjects were thus used as refer-
ence for the Charcot group both at inclusion and at 2
years postinclusion.
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Determination of plasma biomarkers by ECL technology
The Sector Imager 2400 assay platform from MesoScale-
Diagnostics (MSD, Gaithersburg, USA) was used for
analysis of plasma biomarkers (for details see www.me-
soscale.com). This high sensitivity electrogenerated
chemiluminescence technique (ECL) has a low limit of de-
tection and a wide dynamic range as was described in
more detail in a previous study [12]. Matched pairs of
antibodies, i.e. capture antibody (CA) and biotinylated de-
tection antibody (DA), were used. Standard curves were
created using human recombinant proteins (hRP). Plasma
was mounted on uncoated plates from MSD (L15XA). IL-
8 CA: monoclonal mouse IgG1κ (PeproTech cat no. 500-
M08), IL-8 DA and hRP (PeproTech cat no. 900-K18). IL-
6 CA: monoclonal mouse IgG1 (Biotechne R&D Systems
cat no. MAB2062), IL-6 DA: affinity purified polyclonal
goat IgG (Biotechne R&D Systems cat no. BAF206). TNF-
α CA/DA/hRP: PeproTech cat no. 900-K25. IL-1β CA:
monoclonal mouse IgG1 (Biotechne R&D Systems cat no.
MAB601), IL-1β DA: affinity purified polyclonal goat IgG
(Biotechne R&D Systems cat no. BAF201), IL-1β hRP
(Prospec cat no. cyt-208). IL-1RA CA/DA/hRP: Pepro-
Tech cat no. 900-K474. Antibodies were optimized by
checkerboard titrations and subsequent control of stand-
ard curves. Plasma from Charcot, diabetic controls and
healthy subjects were mounted on the same plate to
minimize inter-group variability. Inter-assay variations
were <5 %.
















Age (median- range, years) 61 (42–87) 63 (42–87) 55 (20–94) 57 (20–94) 58 (24–78)
Gender (n)
Females 1012 101011 8 8 9
Males 16 16 12 12 11
Diabetes type 1/2 (n) 11/1517 11/1516 6/14 6/14 -
Diabetes duration (years) 25 ± 4 - 14 ± 6 - -
Debut foot symptoms (weeks, median-range) 8.4 (1–24) - - - -
Systolic blood pressure (mmHg) 149 ± 6 148 ± 6 127 ± 4 - 138 ± 4
Diastolic blood pressure (mmHg) 80 ± 3 80 ± 3 76 ± 2 - 81 ± 3
Arterial toe pressure (mmHg)
Charcot foot 114112 ± 11 122 ± 8 115 ± 4 - -
Contralateral foot 129128 ± 8 119 ± 7 114 ± 5 - -
Skin temperature (°C)
Charcot foot 31.331.6 ± 0.8a 29.7 ± 0.7 30,0 ± 0,4 - -
Contralateral foot 28.8 ± 0.9 29.3 ± 0.7 30,2 ± 0,4 - -
Pain at rest (n) 4 0 0 - -
Pain at weight bearing (n) 17 0 0 - -
Foot distorsion (n) 4 4 0 - 0
Total contact cast (months) - 7.7 ± 1.0 - - -
Charcot pattern I/II/III/IV/V (n) 2/16/57/0/3 - - - -
Nephropathy/Cardiac disease (n) 7/4 7/4 2/1 2/1 0/0
Hb (g/L) 127 ± 3 129 ± 3 136 ± 2 139 ± 3 143 ± 5
S-CRP (mg/L) 10.611.2 ± 3b,c 10.09.8 ± 2d,e 3.6 ± 0,8 3.8 ± 0,8 2.7 ± 0,7
SR (mm) 28.831.1 ± 6f,g 23 ± 5 11 ± 2 10 ± 2 6 ± 4
S-Kreatinin (μmol/L) 112116 ± 19 101 ± 12 83 ± 8 89 ± 7 78 ± 5
HbA1c (mmol/mol) 60 ± 3 64 ± 2 58 ± 3 56 ± 2 -
HbA1c (%) 7.8 ± 0.3 7.4 ± 0.3 7.5 ± 0.2 7.3 ± 0.2 -
Mean ± SEM when not given differently. ap = 0.0100.0100.007 Charcot foot versus contralateral foot at inclusion. bp = 0.028 for Charcot at inclusion versus
diabetic controls at inclusion. cp = 0.015 for Charcot at inclusion versus healthy. dp = 0.0380.030 Charcot end of study vs diabetic controls +2y. ep = 0.022 Charcot
end of study vs healthy. fp =< 0.001 Charcot at inclusion versus diabetic controls at inclusion. gp < 0.001 for Charcot at inclusion versus healthy. All other
differences are not significant. Charcot pattern I-V on radiographs as described by Sanders and Frykberg (see ref: Papanas and Maltezos, [13])
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Radiography
Radiographs of both feet were performed in supine pos-
ition with dorso-plantar, oblique and lateral projections
as well as weight-bearing in frontal and lateral projec-
tions. Examinations followed a preset schedule starting
within a week after inclusion and subsequently 6, 12, 18
and 24 months postinclusion. MRI was performed on a
1.5 T Siemens Magnetom Symphony with supine patient
and feet first into the gantry. All examinations were
performed with a head-neck surface coil and feet in
flexed position. Each foot was examined with 4
sequences without intravenous contrast medium: T1, T2,
T2 3d and STIR sequences in sagittal, transverse and
coronary positions. Intravenous contrast was followed by
T1-sequences in transverse and sagittal projections.
Charcot classification
For anatomical classification of Charcot we used the
system described by Sanders and Frykberg with five
different patterns depending on the areas of the foot
affected [13]: Pattern I: metatarsophalangeal and inter-
phalangeal joints; Pattern II: tarso-metatarsal joints;
Pattern III: naviculocuneiform, talonavicular and calca-
neocuboid joints; pattern IV: ankle and subtalar joints;
Pattern V: calcaneus (Table 1). A modified Eichenholz
staging based on plain X-rays as described by Sella and
Barrette [14], was used for disease characteristics and
comprises 5 stages: Stage 0 (warm, reddened, swollen
foot and normal radiographs), stage 1 (clinical findings
and radiographic cysts, erosions, localized osteopenia
and occasionally diastases), stage 2 (joint subluxation),
stage 3 (dislocation and arch collapse), stage 4 (healed
stage of bony process) (Table 1). Inflammation in the
soft-tissue and bony structures of the foot (edema), were
identified by MRI and summarized in Table 2.
Statistical methods
As the assay platform used for biomarker analysis in the
current study is significantly more sensitive than that of
colorimetric ELISAs, we chose to base our power
analysis on the standard deviations (SD) obtained from
pre-study measurements of individual cytokines. A mean
of the SD of all the individual cytokines of the study was
used as a basis for calculation of sample size. ANOVA
test of 3 groups with a minimum detectable difference in
means (=20), mean SD (=32), power (=0.80) and alpha
(=0.05) required 51 patients.
The tested variables (biomarkers) were measured at
the continuous level over time and a comparison was
made between the 3 independent study groups for each
individual biomarker at inclusion and at 2 years postin-
clusion by means of 1-way repeated measures ANOVA
followed by the Holm-Ŝidak test. When applicable (nor-
mally distributed data), this model was also used for
comparisons between the 3 study groups for blood pres-
sure, Hb, CRP, SR and S-kreatinin (Table 1). This statis-
tical model ensures that the probability of incorrectly
rejecting the null hypothesis for any of the pairwise
comparisons in the family does not exceed alpha,
thereby controlling the familywise error rate (FWE) and
setting the alpha value according to the Ŝidak correction
of Bonferroni inequality. This stepwise method is gener-
ally more powerful than the corresponding single-step
procedures. The Holm-Ŝidak test applies an accept/re-
ject criterion on a sorted set of null hypothesis, starting
from the lower p-value and going up to the acceptance
of null hypothesis. The Ŝidak formula is: Ŝidak corrected
alpha = 1 - (1 - α)1/k where k (=3 in our study) is the
number of comparisons performed for each individual
biomarker. The Ŝidak procedure has slightly more power
than the Bonferroni procedure when alpha = .05. A
multiplicative model was assumed more accurate for the
current data and therefore the logarithms of measure-
ments have been used for the comparisons. Comparisons
between 2 datasets of individual biomarkers within the
Charcot group (e.g. inclusion vs. 4 months) and com-
parison between groups (Charcot and diabetic controls)
of a variable that failed normal distribution (HbA1c),
were done by the non-parametric Wilcoxon rank sum
test (Table 1).
Results
Clinical and demographic data are presented in Table 1.
Radiographic data are presented in Table 2. Tables 1 and 2
have in part been presented in a previous study [12]. One
patient had no radiographic data after 18 months into the
study as the patient chose to interrupt participation.
IL-6
Plasma IL-6 (pg/ml) was not significantly different
between Charcot patients, diabetic controls and Healthy
at inclusion (p = 0.64) or at 2 years (p = 0.22). Plasma
Table 2 Staging of radiographic changes in the Charcot
arthropathy foot as described by Sella and Barrette [14] based
on weight-bearing radiographic examinations of the diseased
foot and inflammation/bone edema on MRI
Radiographs Inclusion 1 W 6 M 12 M 18 M 24 M
Stage 0 4 3 0 0 0 0
Stage 1 3 3 2 0 0 0
Stage 2 911 911 911 68 45 0
Stage 3 10 10 10 5 5 0
Stage 4 0 1 5 15 17 2527
MRI Inclusion 1 W 6 M 12 M 18 M 24 M
Soft tissue edema 2223 2223 1819 14 7 0
Bone marrow edema 18 18 15 13 5 0
Numbers in table are number of patients
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IL-6 in Charcot patients was significantly elevated at 4
months versus inclusion (p < 0.001) but did not differ
significantly between inclusion and 2 years postinclusion
(p = 0.19) (Fig. 2).
IL-8
Plasma IL-8 (pg/ml) was not significantly different
between Charcot patients, Diabetes control patients and
Healthy subjects at inclusion into the study (p = 0.83) or
at 2 years postinclusion (p = 0.45). Plasma IL-8 in
Charcot patients had not changed significantly at 4
months (p = 0.91) or at 2 years (p = 0.35) versus inclu-
sion value (Fig. 3).
TNF-α
Plasma TNF-α (pg/ml) in diabetic controls was signifi-
cantly higher at inclusion versus healthy (p = 0.005) and
versus Charcot (p = 0.005) but did not show significance
between Charcot and healthy (p = 0.64) (Fig. 4). At 2
years postinclusion, plasma TNF-α was significantly higher
in diabetic controls versus Charcot (p = 0.001) and versus
healthy (p = 0.015) whereas difference between Charcot
and healthy was not significant (p = 0.53). TNF-α in
Charcot patients was significantly higher at 4 months
versus inclusion (p = 0.02) but not at 2 years versus
inclusion (p = 0.44).
IL-1β
Plasma IL-1β at inclusion was significantly higher for dia-
betic controls vs. Charcot (p = 0.029) but not vs. healthy
(p = 0.16) or between Charcot and healthy (p = 0.29)
(Fig. 5). At 2 years postinclusion, IL-1β was significantly
higher in diabetic controls versus Charcot (p = 0.027) but
not versus healthy (p = 0.16) or between Charcot and
healthy (p = 0.27). IL-1β in Charcot patients was not
significantly elevated at 4 months versus inclusion value
(p = 0.06) or at 2 years versus inclusion (p = 0.26).
Fig. 2 Plasma IL-6 (pg/ml) in Charcot patients (n = 28), diabetes control patients (n = 20) and healthy donors (n = 20). IL-6 was not significantly
different between the 3 groups at inclusion (p = 0.64) or at 2 years (p = 0.22). ***P < 0.001 for Charcot at 4 months versus Charcot at inclusion.
Charcot at 2 years was not different from Charcot at inclusion (p = 0.19). Mean ± SEM
Folestad et al. Journal of Foot and Ankle Research  (2015) 8:72 Page 6 of 12
IL-1RA
Plasma IL-1RA at inclusion was significantly lower for
healthy versus diabetic controls (p = 0.034) and versus
Charcot (p = 0.004) but did not differ significantly be-
tween Charcot and diabetic controls (p = 0.45) (Fig. 6).
At 2 years postinclusion, IL-1RA was significantly lower
for healthy versus diabetic controls (p = 0.017) and versus
Charcot (p < 0.001) but did not differ significantly
between Charcot and diabetic controls (p = 0.20). IL-1RA
in Charcot patients was significantly higher at 4 months
versus inclusion (p < 0.001) but not at 2 years vs. inclusion
(p = 0.85).
Fig. 3 Plasma IL-8 (pg/ml) in Charcot patients (n = 28), diabetes control patients (n = 20) and healthy donors (n = 20). IL-8 was not significantly
different between the 3 groups at inclusion (p = 0.83) or at 2 years (p = 0.45). IL-8 in Charcot patients at inclusion did not differ from Charcot
at 4 months (p = 0.91) or at 2 years (p = 0.35). Mean ± SEM
Fig. 4 Plasma TNF-α (pg/ml) in Charcot patients (n = 28), diabetes control patients (n = 20) and healthy donors (n = 20). §P = 0.005 for diabetic
controls versus healthy, §§P = 0.005 for diabetic controls versus Charcot. Difference between Charcot at inclusion and diabetic controls was not
significant (p = 0.64). *P = 0.02 for Charcot at 4 months versus Charcot at inclusion. +P = 0.001 for diabetic controls versus healthy, ++P = 0.015
for diabetic controls versus Charcot. Difference between Charcot and healthy at 2 years was not significant (p = 0.53). Charcot at 2 years was not
different from Charcot at inclusion (p = 0.44). Mean ± SEM
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IL-1RA/IL-1β ratio
The ratio was significantly higher in Charcot patients at
inclusion versus diabetic controls (p = 0.007) and versus
healthy (p = 0.027), but not between diabetic controls
and healthy (p = 0.54) (Fig. 7). At 2 years postinclusion,
the ratio was significantly higher in Charcot patients ver-
sus diabetic controls (p = 0.020) and versus healthy
(p = 0.023), but not between Charcot and healthy (p
= 0.43). Ratio in Charcot patients did not differ be-
tween inclusion and 2 years (p = 0.90).
Discussion
Although radiographs showed significant bone pathology
in a majority of Charcot patients at presentation
(Table 2), we were only able to identify four Charcot
patients with visible callus on radiographs despite that
12 weeks had elapsed since debut of symptoms (8 weeks
for the Charcot group as a whole). The time for bony
callus to appear on radiographs may depend on the loca-
tion of a fracture but will in most cases be visible within
3 weeks of the initial trauma. It is thus conceivable to
assume that bony healing had failed to materialize in
most of our Charcot patients with little proof of progress
beyond the endochondral phase. Several factors could
account for this lack of progress. One is the diabetic dis-
ease per se which, aside from being associated with
higher incidence of fractures than the population as a
whole [15, 16], is prone to develop complications in the
sequel of a fracture by as much as 87 % and often heal
with impaired bone quality [17–19]. Accumulation of
highly reactive agents in diabetic patients, such as
advanced glycation end products (AGE), reactive oxygen
species (ROS) and proinflammatory cytokines (particu-
larly TNF-α), have been linked to these complications.
Besides prolonging the survival of osteoclasts and
inducing cell death (apoptosis) of chondrocytes resulting
in premature destruction of the cartilage callus, these
agents also inhibit the differentiation of osteoblasts
thereby hampering the subsequent mineralization and
remodeling of callus [20]. Another co-morbidity of
Charcot with a potential of negatively affecting bone
healing on multiple levels is the mandatory neuropathy
of the lower limbs [18, 21]. Neuropathic diabetic patients
may suffer vitamin D deficiency causing impaired
mineralization of the bone, have abnormal blood flow
pattern in the lower extremities, higher incidence of
atherosclerotic changes in peripheral arteries, and re-
duced numbers of periostal mechanoreceptors of im-
portance for fracture union [18, 21]. In addition, recent
studies have revealed that neuropeptides from auto-
nomic and sensory neurons are able to influence bone
formation and fracture healing by direct actions on
osteoblastic and osteoclastic cells [21]. It is however the
impaired sensitivity in the neuropathic foot which is
considered to be of paramount importance for for the
development of Charcot arthropathy [22] as the patients,
Fig. 5 Plasma levels of IL-1β (pg/ml) in Charcot patients (n = 28), diabetes control patients (n = 20) and healthy donors (n = 20). §P=0.029 for dia-
betic controls versus Charcot. Differences were not significant between diabetic controls and healthy (p=0.16) or between Charcot and healthy (p
= 0.29). +P=0.027 for diabetic controls versus Charcot. Differences were not significant for diabetic controls versus healthy (p=0.016) or between
Charcot and healthy (p = 0.28). Charcot at inclusion was not different from Charcot at 4 months (p = 0.07) and or at 2 years (p = 0.26). Mean
± SEM
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unable to recognize the severity of ongoing pathology,
continue to weight-bear on the diseased foot [18, 21],
thereby complicating the already complex dynamics of
inflammation and fracture healing. A significant and
rapidly expanding knowledge base of signaling pathways
and the complex cross-talk between these pathways has
continuously added to our understanding of the role
played by the innate and adaptive immune systems, en-
zymes and hormones in bone repair and remodeling [3,
23]. This has led to steadily increasing numbers of bio-
logical agents targeting specific components of the bone
repair cascade with the aim of improving the outcome
[24]. Nonetheless, our current understanding of the bio-
logical mechanisms regulating the pathology and recovery
of Charcot arthropathy is almost entirely circumstantial in
nature. In two recent studies to be discussed below, we
presented evidence of the important role played by proin-
flammatory cytokines belonging to the Th17 subset of T
helper cells [12] and by mediators of two major bone-
regulating pathways [10] for bone healing in Charcot ar-
thropathy patients. In the current study, we extended our
investigation to the THh1/Th2 subset of proinflammatory
cytokines.
A comparison of diabetic neuropathic control patients
and with healthy individuals revealed no significant dif-
ferences as for IL-6, IL-8 and IL-1β, whereas TNF-α was
significantly higher in diabetic controls. Although previ-
ous studies have linked diabetes to high systemic levels
of proinflammatory cytokines [25–27], therapeutic regu-
lation of hyperglycemia has proven a rather effective
measure of normalizing cytokine levels [25, 26] which
could suggest that the reports showing systemic proin-
flammatory cytokines in diabetic patients to range from
lower to equal or higher than healthy individuals are
linked to the duration and state of the patient diabetic
disease at the time of sampling, although differences in
assay type and sensitivity could have played in [28]. In
two previous studies investigating monocytes from acute
Fig. 6 Plasma levels of IL-1RA (pg/ml) in Charcot patients (n = 28), diabetes control patients (n = 20) and healthy donors (n = 20). §P = 0.034 for
diabetic controls versus healthy, §§P = 0.004 for Charcot versus healthy. Difference between Charcot at inclusion and diabetic controls was not
significant (0.45). ***P < 0.001 for Charcot at 4 months versus Charcot at inclusion. +P = 0.017 for diabetic controls versus healthy, ++P < 0.001 for
Charcot versus healthy. Difference between Charcot at inclusion and Charcot at 2 years was not significant (p = 0.85). Mean ± SEM
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Charcot patients, results showed increased levels of
proinflammatory immune phenotype [29] and increased
numbers of CD-14 positive monocytes with a potential
of transforming into osteoclasts [30]. They also showed
slightly but significantly elevated serum IL-6, TNF-α and
IL-1β in Charcot versus healthy [29] and higher TNF-α
but not IL-1β in Charcot versus diabetic controls and
healthy [30]. Our results showing all proinflammatory
cytokines in Charcot patients at presentation to be
below or at the level of diabetic controls are thus in op-
position to the previous studies. We cannot offer a
plausible explanation to these differences but emphasize
that our study had a larger number of patients (66 in
our study vs. 27 by Mabilleau and 26 by Uccioli) and
used a significantly more sensitive technique to analyze
biomarkers having with a dynamic range of 106 as com-
pared to 103 for colorimetric ELISA [31, 32]. It may ap-
pear paradoxical that proinflammatory cytokines in
Charcot patients at presentation are below or at the level
of diabetic controls when considering that the acute
Charcot foot presents itself with soft tissue, cartilage and
bone pathology and the classical features of a local in-
flammatory reaction, i.e. a red, hot and swollen foot [5].
A plausible explanation could be that proinflammatory
cytokines such as TNF-α and IL-1β, although important
for the initiation of tissue inflammation following
trauma [1, 3], only last a few days and constitute a
small portion of the great basin of mediators (e.g.
bradykinin, histamine, prostaglandins, substance P) in-
volved in the local regulation of blood flow (flare and
heat reaction) and vascular permeability (swelling) [33]
with the ability to entertain the complex neuro-
inflammatory cascade until optimal healing conditions are
met. Another explanation for the low levels of proinflam-
matory cytokines at Charcot presentation is the counter-
regulatory activation of anti-inflammatory cytokines, such
as IL-4, IL-10 and IL-13, in order to down-regulate poten-
tially harmful levels of proinflammatory cytokines [34, 35].
The latter mechanism is supported by the current results
showing high levels of IL-1RA, the circulating natural an-
tagonist of the potent proinflammatory cytokine IL-1β.






























Fig. 7 IL-1RA/IL-1β ratio in Charcot patients (n = 28), diabetes control patients (n = 20) and healthy donors (n = 20)
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with direct inhibitory effect on IL-1β thereby protecting
the bone from excessive osteoclastic activity [36]. How-
ever, as we also showed high IL-1RA level in diabetic con-
trol patients, it could be inferred that its activity is linked
to the diabetic disease per se as high inflammasome activ-
ity and excessive release of ROS, typical of diabetes [37],
have been shown to induce high levels of IL-1RA [38].
Diabetes as the sole explanation is however contradicted
by the IL-1RA/IL-1β ratio being significantly higher in
Charcot patients due to lower IL-1β being lower than in
diabetic controls. A high ratio at presentation and further
increase during offloading suggest that IL-1β had reached
a harmful level in the diseased foot thus prompting a
counter-regulatory inhibition and a shift of the ratio in an
anti-inflammatory direction. This inhibition of IL-1β may
also explain the contained levels of IL-6 and TNF-α, as
most proinflammatory cytokines which are present at high
levels in the blood of diabetic patients are IL-1-driven and
reduced by blocking its activity [39]. This inhibition ap-
pear however to extend beyond the Th1/Th2 subset of
proinflammatory cytokines as we were recently able to
show a similar containment of IL-17 cytokines belonging
to the Th17 subset in Charcot patients exerting full
weight-bearing at presentation [12].
Although minor movements in a fracture have been
proven beneficial for bone healing, instability and exces-
sive motion has been shown to cause predominantly
catabolic activity, suppress ingrowth of new blood
vessels, trigger excessive formation of cartilage and
inhibit its subsequent replacement with bone thus
hindering bone from bridging the fracture gap [3].
Stabilization and offloading of the Charcot foot in order to
create a better bio-environment for recovery has therefore
emerged as the most important strategy to prevent further
deterioration and reverse the pathological processes [5].
Such a mechanism could explain the current results show-
ing that IL-6 and TNF-α had begun to increase shortly
after TCC treatment when unfavorable healing conditions
caused by continued weight-bearing on the diseased foot
had ceased. A similar increase by IL-17 family cytokines
shortly after TCC in Charcot patients [12] lend
further support to offloading being a critical factor
which interrupts the vicious cycle caused by contin-
ued weight-bearing and sets the wheels of bone repair
in motion. Although it may seem paradoxical that
increased activity by inflammatory cytokines is beneficial
to the healing process, there is ample evidence to show
that a secondary or late phase of proinflammatory media-
tors is in fact mandatory for bone healing to proceed
normally [3, 40]. Proinflammatory cytokines, such as
TNF-α, IL-1β, IL-6 and IL-17, have been shown to play a
pivotal role in the initiation of bone mineralization and
remodeling as they, in addition to inducing osteoclast
differentiation, also stimulate angiogenesis and promote
osteoblast differentiation and when lacking cause fracture
healing to be significantly delayed [1, 3]. The importance
of offloading is further emphasized by recent results show-
ing that TCC treatment coincided with a significant
increase by dickkopf-1 (dkk-1) and Wnt ligand-1 (Wnt-1)
[10], two mediators of the bone anabolic Wnt/β-catenin
pathway implicated in bone remodeling [41, 42] and that
an inter-regulatory link exists between proinflammatory
cytokines and the Wnt system [43]. Our results showing
that IL-8 did not change in the aftermath of offloading
treatment could suggest that it had outplayed its most im-
portant role as chemotactic agent, i.e. to attract leuko-
cytes, in the early post-injury phase. An interesting
observation of the study was that although radiographs
and MRI showed mineralized bone and no visible edema
after 2 years, IL-1RA/IL-1β ratio remained high thus sig-
nifying a need for continued anti-inflammatory activity. A
plausible reason for such a defensive measure in the
chronic phase of Charcot could be that renewed weight-
bearing on the Charcot foot, often characterized by bone
deformities, will lead to unnatural high pressure on areas
of the foot leading to exacerbated inflammation and
microdamage [44]. The chronic phase being highly active
from a biological point of view was further supported by
the high bone remodeling activity of sclerostin and Wnt
inhibitory factor-1 (Wif-1), mediators of the bone anabolic
Wnt/β-catenin pathway, two years after Charcot presenta-
tion [10].
A limitation of the current study is the small sample
size. We believe that the use of a high-sensitivity platform
for analysis of biomarkers compensated this limitation by
showing that the number of patients in the study was
sufficient to achieve a power of 0.8 in an ANOVA
comparison of three groups. The current protocol
was further strengthened by repetitive measurements
of biomarkers yielding a trajectory in support of the
individual time points as well as by the well-defined
groups of the study.
Conclusions
In conclusion, proinflammatory cytokines play a critical
role in the early and late phase of bone fracture repair.
Our results showing that proinflammatory cytokines
were not above the level of diabetic controls at Charcot
presentation, when patients exerted full weight-bearing
on the diseased foot, and increased significantly after
offloading, support TCC as a key factor setting off the
secondary cascade of inflammatory cytokines responsible
for the coupled bone remodeling phase. High IL-1RA/
IL-1β ratio in the chronic phase of Charcot is probably a
protective measure to reduce further tissue damage
induced by renewed full weight-bearing on a de-
formed foot with impaired bone quality. Additional
work is needed to more clearly define the complex
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cross-talk between pathways involved in the healing
of the Charcot foot.
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